Adaptimmune Therapeutics's total assets for Q1 2025 were $158.07M, a decrease of -35.73% from the previous quarter. ADAP total liabilities were $195.50M for the fiscal quarter, a -16.49% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.